Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (October 2023)
25 slides from Century Therapeutics's investor presentation, Oct 3, 2023
Slide 1: Corporate Overview October 2023
CENTURY THERAPEUTICS Corporate Overview October 2023
Slide 2: Forward-looking statements
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical fact
Slide 3: Investment Thesis
3 Investment Thesis Next generation platforms for iNK and gamma delta iT candidates Foundational investments in iPSC technology, genetic editing, and manufacturing Experienced team in R&D, immuno - oncology, manufacturing and commercialization Exemplified by FDA clearance of Century’s first IND for
Slide 4: iPSC Platform
iPSC Platform
Slide 5: Building a next generation allogeneic cell therapy platform
5 Building a next generation allogeneic cell therapy platform Gene Editing • Proprietary gene editing platform • CRISPR MAD7 - derived gene editing for precise transgene integration Protein Engineering • Developing proprietary next - generation CARs • Universal tumor targeting platform iPSC Differen
Slide 6: Foundational investments in iPSC know-how and manufacturing
6 Foundational investments in iPSC know - how and manufacturing Established in - house manufacturing accelerates learnings and enables faster product iteration • 53,000 ft 2 facility • Designed to produce multiple immune cell types • Two sites provides optionality and maximizes flexibility iPSC lice
Slide 7: Multiple gene edits iPSC bank
7 Multiple gene edits (KO/KI) iPSC bank Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates Engineered iPSC Master Cell Bank (MCB) Advantages of Century’s Platform P recise CRISPR mediated homology directed repair reduces off - target integration
Slide 8: Potential to drive durable responses with engineering to resist immune rejection
8 Potential to drive durable responses with engineering to resist immune rejection Allo - Evasion TM edits + repeat dosing = potential greater durability Next - wave of allogeneic cell therapies must solve for challenge of rejection With Allo - Evasion TM engineering Without Allo - Evasion TM engine
Slide 9: 1.0 designed to overcome major pathways of host vs graft rejection
9 Allo - Evasion TM 1.0 designed to overcome 3 major pathways of host vs graft rejection 1. Deletion of β 2M, a protein required to express HLA - 1 on the cell surface prevents recognition by CD8 T cells 2. Knock out of CIITA eliminates HLA - II expression to escape elimination by CD4 T cells 3. Kno
Slide 10: 3.0 Provides Additional Protection Against NK Cell Killing
10 Allo - Evasion TM 3.0 Provides Additional Protection Against NK Cell Killing 1. Deletion of β 2M, a protein required to express HLA - 1 on the cell surface prevents recognition by CD8 T cells 2. Knock out of CIITA eliminates HLA - II expression to escape elimination by CD4 T cells 3. Knock - in o
Slide 11: Expression of HLA-E + HLA-G further protects from NK cell killing
11 Expression of HLA - E + HLA - G further protects from NK cell killing HLA - E HLA - G NKG2A KIRs, LIRs Activating ligand Activating receptor Proof - of - Concept Study with HLA - I Null K562 Cells Engineered with HLA - E and HLA - G 0 . 1 2 5 0 . 2 5 0 . 5 1 2 4 8 1 6 3 2 0 20 40 60 80 100 Donor
Slide 12: Pipeline
Pipeline
Slide 13: Product candidate pipeline across cell platforms and targets
13 Product iPSC Platform Targets Indications Discovery Preclinical Clinical Collaborator P1 P2 P3 CNTY - 101 iNK CD19 B - Cell Malignancies CNTY - 102 iT CD19 + CD22 B - Cell Malignancies CNTY - 107 iT Nectin - 4 Solid Tumors Programs in Collaboration CNTY - 104 iNK/iT Multi - specific Acute Myeloid
Slide 14: Promise of allogeneic cell therapies in lymphoma
14 Promise of allogeneic cell therapies in lymphoma Large unmet need remains despite progress with autologous cell therapies • ~25% of eligible patients receive CAR - T therapy 1 • ~35% of patients achieve long - term remission even in earlier lines of therapy 1 Off - the - shelf modalities approach
Slide 15: Delivering on our vision to change the cell therapy treatment paradigm
15 Delivering on our vision to change the cell therapy treatment paradigm • Goal to improve durability, tolerability and ease of outpatient administration • Potential to e liminate need for lymphodepletion with subsequent cycles of therapy • First CD19 - targeted agent to test durability benefit of
Slide 16: CNTY-101 shows strong pre-clinical anti-tumor activity
16 CNTY - 101 shows strong pre - clinical anti - tumor activity In Vitro Serial killing assay Robust activity against lymphoma xenograft Borges, et al, ASH 202 1
Slide 17: ELiPSE-1: Ongoing first-in-Human Study
17 ELiPSE - 1: Ongoing first - in - Human Study CNTY - 101 in patients with patients with relapsed/refractory CD19+ B - cell lymphomas Study to assess: Impact of Allo - Evasion TM on iNK cell persistence and PK after multiple dosing (Schedule B) Multiple dose regimen with up to 6 doses with single l
Slide 18: ELiPSE Translational Approach
18 Elipse - 1 Translational Approach MRD= minimum residual disease; CDC=complement - dependent cytotoxicity; ADCC= antibody - dependent cellular cytotoxicity; CAR=chimer ic antigen receptor; cf - DNA=cell free deoxyribonucleic acid Identify optimal dosing regimen Cellular Pharmacokinetics (PK) Asses
Slide 19: CNTY-102: Leveraging the γδ iT platform
19 CNTY - 102: Leveraging the γδ iT platform designed to deliver best - in - class potential HLA - II KO Illustrative construct γδ TCR/CD3 IL - 15/IL15RA HLA - E HLA - G HLA - I KO CD19/CD22 loop CAR Designed to address factors that limit durability of cell therapy in B - cell malignancies • γδ iT c
Slide 20: Vision for winning in solid tumors with γδ iT platform
20 Vision for winning in solid tumors with γδ iT platform Trafficking and infiltration γδ iT cells - tissue homing TME / Immunosuppressive environment Requirement for chemotherapy conditioning Tumor heterogeneity • Novel conditioning regimens • Genetic engineering Challenges Century’s Solution Futur
Slide 21: iPSC-derived γδ T cells effective at tumor control
21 iPSC - derived γδ T cells effective at tumor control as monotherapy and in combination with antibody Millar, et al, SITC 2022 γδ - EGFR - CAR - T cells demonstrate significant CAR killing of ovarian spheroids γδ CAR - T demonstrate additive efficacy in combination with trastuzumab Treatment % TGI
Slide 22: CNTY-107: First in class Nectin-targeted γδ iT cell therapy
22 CNTY - 107: First in class Nectin - 4 targeted γδ iT cell therapy Leveraging the power of the γδ iT cell platform for solid tumors Nectin - 4 has been validated by ADC approaches • Opportunity to address multiple Nectin - 4 positive solid tumors • Potential indications include bladder, breast, pa
Slide 23: Investment Thesis
23 Investment Thesis Next generation platforms for iNK and gamma delta iT candidates Foundational investments in iPSC technology, genetic editing, and manufacturing Experienced team in R&D, immuno - oncology, manufacturing and commercialization Exemplified by FDA clearance of Century’s first IND for
Slide 24: Emerging leader in cell therapies for cancer
Emerging leader in cell therapies for cancer Comprehensive iPSC cell platform For immune effector cells Technical Expertise Genetic and protein engineering, process development and immuno - oncology Foundation in Science Continuing investment in innovation drives R&D State - of - the - art GMP manuf
Slide 25: Thank you.
CENTURY THERAPEUTICS Thank you.
Century Therapeutics — Investor Presentation (October 2023) on 6ix